logo

Blueprint Medicines (BPMC)



Trade BPMC now with
  Date
  Headline
3/3/2021 8:36:04 AM Blueprint : EMA Validates Type II Variation MAA For AYVAKYT For The Treatment Of Advanced Systemic Mastocytosis
2/17/2021 7:07:37 AM Blueprint Medicines Q4 Net Loss $85.7 Mln Or $1.53/shr Vs. Net Loss $66.3 Mln Or $1.35/shr Last Year
10/29/2020 7:44:59 AM Blueprint Medicines Q3 Net Income $634.0 Mln Or $11.16/shr Vs. Net Loss $94.3 Mln Or $1.93/shr Last Year
9/22/2020 7:05:06 AM Blueprint Medicines Announces Positive Top-line Results From EXPLORER And PATHFINDER Trials Of AYVAKIT
9/20/2020 11:51:41 AM Blueprint Medicines Reports ARROW Trial Data At ESMO Virtual Congress 2020
9/4/2020 8:01:44 AM Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
9/1/2020 8:02:43 AM Blueprint Medicines Appoints Fouad Namouni As President, Research & Development
7/30/2020 7:23:35 AM Blueprint Medicines Q2 Net Loss $123.5 Mln Or $2.28/shr Vs. Net Loss $99.7 Mln Or $2.04/shr Last Year
7/24/2020 8:33:48 AM Blueprint Medicines Receives Positive CHMP Opinion For Avapritinib
7/14/2020 1:07:46 AM Blueprint Medicines Collaborates With Roche To Develop &Commercialize Pralsetinib For Patients With RET-Altered Cancers
7/14/2020 1:04:39 AM Roche, Blueprint Medicines Announce Signing Of Licensing And Collaboration Agreement